Top Page
Imagion Biosystems Ltd.
(Sydney:IBX)
Imagion Biosystems Ltd. (IBX) vs. iShares MSCI Australia ETF (EWA)
Imagion Biosystems Ltd. Business Overview & Revenue Model
Imagion Biosystems Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.06M | 2.67M | 1.08M | 473.43K | 232.87K | 205.72K |
| Gross Profit | 376.04K | 2.26M | -279.83K | -3.14M | -2.47M | -2.66M |
| EBITDA | -1.31M | -700.09K | -10.30M | -11.03M | -5.62M | -7.16M |
| Net Income | -2.20M | -2.07M | -12.47M | -9.81M | -6.02M | -5.36M |
Balance Sheet | ||||||
| Total Assets | 932.48K | 2.80M | 4.59M | 9.98M | 14.12M | 14.12M |
| Cash, Cash Equivalents and Short-Term Investments | 883.57K | 2.67M | 227.08K | 4.45M | 13.39M | 13.20M |
| Total Debt | 3.30M | 2.85M | 6.04M | 4.60M | 46.02K | 660.98K |
| Total Liabilities | 4.80M | 5.09M | 8.37M | 5.30M | 809.88K | 1.21M |
| Stockholders Equity | -3.87M | -2.28M | -3.79M | 4.68M | 13.31M | 12.91M |
Cash Flow | ||||||
| Free Cash Flow | -2.89M | -1.27M | -8.51M | -9.21M | -5.29M | -4.63M |
| Operating Cash Flow | -2.89M | -1.27M | -8.32M | -8.70M | -5.07M | -4.62M |
| Investing Cash Flow | 0.00 | 83.74K | -190.38K | -468.73K | -310.09K | -7.86K |
| Financing Cash Flow | 3.39M | 3.61M | 4.29M | -962.06K | 5.15M | 14.52M |
Imagion Biosystems Ltd. Technical Analysis
Imagion Biosystems Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | AU$58.08M | 30.83 | 98.18% | ― | 11.93% | 2.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$169.25M | ― | -111.23% | ― | 12.96% | 40.81% | |
48 Neutral | AU$34.21M | -4.70 | -97.79% | ― | ― | 23.85% | |
45 Neutral | AU$10.77M | -2.11 | ― | ― | -47.02% | 94.37% | |
38 Underperform | AU$49.96M | -5.78 | -37.78% | ― | 2.33% | 12.50% |
Imagion Biosystems Ltd. Corporate Events
Imagion Biosystems has issued a cleansing notice for 10,000,000 new ordinary shares as part of a Convertible Securities Agreement with Mercer Street Global Opportunity Fund, LLC. This issuance is part of their compliance with the Corporations Act, ensuring transparency and adherence to regulatory requirements. The move is expected to bolster Imagion’s financial position, potentially enhancing its market presence and operational capabilities in the medical imaging sector.
Imagion Biosystems Ltd. has announced the issuance of 10 million new ordinary fully paid securities, which will be quoted on the Australian Securities Exchange (ASX) under the code IBX. This move is part of the company’s strategy to enhance its capital base, potentially strengthening its market position and providing additional resources for ongoing research and development efforts.
Imagion Biosystems Ltd. announced the completion of key milestones in its collaboration with Wayne State University, leading to the finalization of the Phase 2 study protocol for its MagSense® HER2 Breast Cancer clinical trial. The company plans to submit an Investigational New Drug application to the FDA in December 2025, with the trial expected to commence in early 2026. The collaboration has resulted in a reduced dose of the imaging agent, optimized MRI sequences, and the potential for AI-ready imaging data, enhancing patient safety and trial efficiency while reducing costs and improving clinical workflow.
Imagion Biosystems has announced positive results from its collaboration with Wayne State University on the MagSense® HER2 Imaging Agent, which is a significant step towards their Phase 2 clinical trial for HER2 breast cancer. The study indicates that a lower dose of the imaging agent is detectable, potentially improving patient safety and care experience. Additionally, optimized imaging protocols and the integration of AI-ready imaging data suggest advancements in diagnostic precision. The company remains on track to submit its Investigational New Drug application to the FDA by the end of 2025, with the Phase 2 study expected to commence in early 2026, pending regulatory approval.
Imagion Biosystems Ltd. announced significant progress in its MagSense® HER2 breast cancer imaging agent program, with plans to file an Investigational New Drug (IND) application with the FDA in Q4 2025. The company has received positive feedback from the FDA, completed a $3.5M capital raising to fund the IND submission and initiate a Phase 2 clinical trial, and achieved a major milestone in manufacturing the MagSense® imaging agent. Additionally, Imagion has entered a collaboration with Wayne State University to optimize MRI protocols and appointed Dr. Nina Webster as a Non-Executive Director to strengthen its strategic capabilities.
Imagion Biosystems Ltd. has announced the issuance of 384,615 new ordinary shares as payment for services provided by investor relations services. This move is part of the company’s strategy to enhance its market presence and investor engagement, potentially impacting its operational dynamics and stakeholder relations positively.
Imagion Biosystems has issued 384,615 new ordinary shares to a service provider as a strategic move to conserve cash reserves. The shares were priced using a 10-day Volume Weighted Average Price of 3.94 cents per share, with a six-month trading lock applied to half of the issued shares. This issuance reflects Imagion’s efforts to manage its financial resources while continuing to focus on its core mission of improving cancer detection, potentially impacting its operational efficiency and stakeholder confidence.
Imagion Biosystems Ltd. has announced the quotation of 17,123,288 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective October 10, 2025. This move is part of the company’s strategic efforts to enhance its financial flexibility and support its ongoing operations, potentially strengthening its market position and providing value to its stakeholders.
Imagion Biosystems has announced the issuance of 17.1 million new shares at 2.92 cents each, following the conversion of 500,000 convertible notes held by Mercer Street Global Opportunity Fund. This move is part of a strategy to reduce debt and improve the company’s balance sheet, reflecting a positive impact on its financial health and potentially strengthening its market position in the healthcare industry.
Imagion Biosystems has completed the manufacturing of its MagSense® HER2 Breast Cancer Imaging Agent, marking a significant milestone in its Phase 2 clinical trial program. The company is collaborating with Siemens and Wayne State University to optimize imaging protocols, aiming to improve particle visualization and develop AI techniques. The recent AU$3.5 million capital raise will support the HER2 Phase 2 clinical trial and other cancer programs, with no expected impact from the U.S. federal government shutdown on the IND application timeline.
Imagion Biosystems Ltd. has announced the quotation of 12,292,437 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of September 30, 2025. This move reflects the conversion of options or other convertible securities, potentially enhancing the company’s liquidity and market presence.
Imagion Biosystems Limited has issued a cleansing notice related to the issuance of 12,292,437 new ordinary shares under a Convertible Securities Agreement with Mercer Street Global Opportunity Fund, LLC. This strategic move aims to bolster the company’s financial position and support its ongoing efforts in advancing its proprietary cancer detection technology. The issuance of these shares without disclosure under the Corporations Act signifies compliance with regulatory requirements, reflecting Imagion’s commitment to transparency and adherence to legal standards. This development could potentially strengthen Imagion’s market position and provide additional resources for its technological advancements, benefiting stakeholders and enhancing its competitive edge in the healthcare industry.
Imagion Biosystems Ltd. announced a change in the director’s interest, with Robert Romeo Proulx acquiring 1,666,667 ordinary shares and 1,666,667 listed options. This acquisition, priced at $0.015 per ordinary share, reflects a strategic move that may influence the company’s market position and investor confidence, potentially impacting its operations and stakeholder interests.
Imagion Biosystems Ltd. announced the issuance of 26,250,000 unquoted equity securities, specifically options expiring on September 21, 2028, with an exercise price of $0.04. This move is part of previously announced transactions and reflects the company’s ongoing efforts to strengthen its financial position and support its strategic initiatives in the biotechnology sector.
Imagion Biosystems Ltd. announced the approval of issuing 3,666,667 ordinary shares to Pitt Street Research Pty Ltd as compensation for a year’s worth of analyst research coverage. This move, approved at the recent general meeting, aims to strengthen the company’s market position by ensuring continued analytical insights and support, which could enhance investor confidence and stakeholder engagement.
Imagion Biosystems Ltd. has announced the quotation of new securities on the Australian Securities Exchange (ASX), including 233,333,334 options expiring in December 2027 and 188,333,333 fully paid ordinary shares. This move is part of previously announced transactions and is expected to strengthen the company’s financial position, potentially enhancing its market presence and operational capabilities.
Imagion Biosystems has successfully completed the settlement of Tranche 2 of its $3.5 million Placement, raising $2.85 million in funds. These proceeds will be used to advance the company’s MagSense® imaging technology, specifically targeting the HER2 breast cancer indication, and to initiate studies for prostate and ovarian cancer. The company plans to commence a Phase 2 clinical trial for HER2 breast cancer, with objectives including the submission of an IND application to the FDA, completion of drug manufacturing, filing of new IP applications, and collaborations with MRI experts to enhance their imaging platform.
Imagion Biosystems Ltd. announced the results of its general meeting, where all proposed resolutions were carried. The resolutions included the ratification and approval of share placements, issuance of options to directors and brokers, and amendments to convertible notes. These approvals are expected to support the company’s financial strategies and operational growth, potentially enhancing its market position and stakeholder value.
Imagion Biosystems Ltd. announced progress towards its IND submission and the commencement of a Phase 2 Clinical Trial for its MagSense® HER2 breast cancer agent by the end of 2025. The company’s innovative imaging technology aims to enhance cancer detection accuracy, offering a significant business opportunity and addressing a critical gap in the current diagnostic landscape. The recent Extraordinary General Meeting highlighted the importance of funding for the commercialization of this new class of imaging technology, which has garnered market support and increased shareholder interest.
Imagion Biosystems Ltd. announced a change in the director’s interest, with Dr. Nina Webster acquiring 565,211 ordinary shares through an on-market purchase. This acquisition reflects a significant personal investment by Dr. Webster, potentially indicating confidence in the company’s future prospects and strategic direction.
Imagion Biosystems Limited has announced significant progress in its MagSense® HER2 Breast Cancer diagnostic imaging program, with the commencement of manufacturing for the Phase 2 clinical trial. The company has also secured $3.5 million in funding and appointed Dr. Nina Webster as a Non-Executive Director to strengthen its leadership team. Additionally, Imagion has initiated a collaboration with Wayne State University to optimize imaging protocols, supported by Siemens Healthineers, which could enhance the diagnostic utility of its molecular MRI technology.